Health Canada consulting on new biosimilar guidance document
Health Canada has published a draft amended guidance document covering information and submission requirements for biosimilar biologic drugs. If implemented, Health Canada...Read More
4(2)(b) or not 4(2)(b) – Federal Court of Appeal answers the question in COMPLERA patent listing decision
On October 9, 2012, the Federal Court of Appeal released its Reasons for Judgment holding Canadian Patent No. 2,512,475 was not eligible...Read More